About DurVena

DurVena is commercializing a photochemical tissue passivation therapy (“PTP”) that strengthens venous tissue and improves long term vein graft patency. Rose Bengal dye, a photo-initiator with a long history of medical use, is applied to the exterior of the harvested vein. The coated vein is exposed to LED light, which activates the dye creating additional collagen crosslinks in the extra cellular matrix of the adventitia of the vein. The collagen crosslinks increase the tissue strength and decrease the elasticity. Extensive pre-clinical testing of PTP in both small and large animals has been published in top peer-reviewed journals showing a significant increase in vein stiffness (5x), a comparable reduction in vein expansion, and a reduction in intimal hyperplasia (70% reduction), a precursor of stenosis and graft failure.



This novel therapy is licensed from Mass General Hospital and is being driven by an accomplished team of business professionals with several successful exits ($1.25B in total investor returns) and extensive experience with start-up medical device development in this market sector. Broad claims covering the PTP method and devices for vein graft preparation have been issued around the world, and a comprehensive international portfolio of related claims are being prosecuted.